Literature DB >> 14569130

A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology.

R M Giusti, J L Rutter, P H Duray, L S Freedman, M Konichezky, J Fisher-Fischbein, M H Greene, B Maslansky, A Fischbein, S B Gruber, G Rennert, R D Ronchetti, S M Hewitt, J P Struewing, J Iscovich.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14569130      PMCID： PMC1735297          DOI： 10.1136/jmg.40.10.787

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  32 in total

Review 1.  Management of hereditary breast and ovarian cancer.

Authors:  Hideko Yamauchi; Junko Takei
Journal:  Int J Clin Oncol       Date:  2017-11-28       Impact factor: 3.402

2.  Incidence of subsequent pancreatic adenocarcinoma in patients with a history of nonpancreatic primary cancers.

Authors:  Sunil Amin; Russell B McBride; Jennie K Kline; Elana B Mitchel; Aimee L Lucas; Alfred I Neugut; Harold Frucht
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 3.  Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer.

Authors:  Alessandra Modena; Roberto Iacovelli; Aldo Scarpa; Matteo Brunelli; Chiara Ciccarese; Emanuela Fantinel; Davide Bimbatti; Francesco Massari; Guido Martignoni; Giampaolo Tortora
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

4.  Familial prostate cancer.

Authors:  Veda N Giri; Jennifer L Beebe-Dimmer
Journal:  Semin Oncol       Date:  2016-08-18       Impact factor: 4.929

5.  Germline BRCA mutations denote a clinicopathologic subset of prostate cancer.

Authors:  David J Gallagher; Mia M Gaudet; Prodipto Pal; Tomas Kirchhoff; Lisa Balistreri; Kinjal Vora; Jasmine Bhatia; Zsofia Stadler; Samson W Fine; Victor Reuter; Michael Zelefsky; Michael J Morris; Howard I Scher; Robert J Klein; Larry Norton; James A Eastham; Peter T Scardino; Mark E Robson; Kenneth Offit
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

6.  Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.

Authors:  Richard Walker; Alyssa Louis; Alejandro Berlin; Sheri Horsburgh; Robert G Bristow; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

7.  Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations.

Authors:  Ilir Agalliu; Robert Gern; Suzanne Leanza; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 8.  The role of the BRCA2 gene in susceptibility to prostate cancer revisited.

Authors:  Elaine A Ostrander; Miriam S Udler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

9.  Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

Authors:  Julie L Boyle; Andrew W Hahn; Ashley L Kapron; Wendy Kohlmann; Samantha E Greenberg; Timothy J Parnell; Craig C Teerlink; Benjamin L Maughan; Bing-Jian Feng; Lisa Cannon-Albright; Neeraj Agarwal; Kathleen A Cooney
Journal:  JCO Precis Oncol       Date:  2020-03-04

10.  Selected aspects of inherited susceptibility to prostate cancer and tumours of different site of origin.

Authors:  Cezary Cybulski
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.